{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:38:34Z","timestamp":1789666714882,"version":"4.0.1"},"reference-count":125,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.mayocp.2025.08.019","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:22:48Z","timestamp":1764908568000},"page":"136-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cardiovascular Toxicity of Fluoropyrimidines: What We Know"],"prefix":"10.1016","volume":"101","author":[{"given":"Ziad","family":"Zalaquett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neehal","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Chedid","family":"El Helou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Moudgil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2025.08.019_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","article-title":"Fluoropyrimidine-induced cardiotoxicity","volume":"124","author":"Depetris","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.mayocp.2025.08.019_bib2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.019_bib3","first-page":"627","article-title":"5-Fluorouracil and capecitabine: assessment and treatment of uncommon early-onset severe toxicities associated with administration","volume":"22","author":"Brutcher","year":"2018","journal-title":"Clin J Oncol Nurs"},{"issue":"7","key":"10.1016\/j.mayocp.2025.08.019_bib4","first-page":"33","article-title":"Toxicity of 5-fluorouracil","volume":"13","author":"Macdonald","year":"1999","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.mayocp.2025.08.019_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection","volume":"9","author":"Morelli","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib6","first-page":"311","article-title":"[Cardiovascular disorders in the course of antimitotic infusions at high doses. 30 clinical cases]","volume":"26","author":"Gaveau","year":"1969","journal-title":"Anesth Analg (Paris)"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/106002809402800314","article-title":"Fluorouracil cardiotoxicity","volume":"28","author":"Anand","year":"1994","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003495-199957040-00003","article-title":"Cardiotoxicity of the antiproliferative compound fluorouracil","volume":"57","author":"Becker","year":"1999","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.019_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/030089168206800609","article-title":"Cardiac toxicity of 5-fluorouracil: a study on 1083 patients","volume":"68","author":"Labianca","year":"1982","journal-title":"Tumori"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.019_bib10","first-page":"PI51","article-title":"Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy\u2014a survey of 427 patients","volume":"8","author":"Tsavaris","year":"2002","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib12","doi-asserted-by":"crossref","first-page":"e606","DOI":"10.1634\/theoncologist.2019-0762","article-title":"Fluoropyrimidine-associated cardiotoxicity: a retrospective case-control study","volume":"25","author":"Raber","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40880-018-0292-1","article-title":"Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study","volume":"38","author":"Peng","year":"2018","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/ph16040510","article-title":"Redefining the incidence and profile of fluoropyrimidine-associated cardiotoxicity in cancer patients: a systematic review and meta-analysis","volume":"16","author":"Lu","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1989.7.4.509","article-title":"Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study","volume":"7","author":"Rezkalla","year":"1989","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2025.08.019_bib16","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/0284186X.2019.1711164","article-title":"Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer","volume":"59","author":"Dyhl-Polk","year":"2020","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2025.08.019_bib18","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1053\/j.ajkd.2018.06.026","article-title":"Cardiovascular diseases in African Americans: fostering community partnerships to stem the tide","volume":"72","author":"Mensah","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mayocp.2025.08.019_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102230","article-title":"Ranking age-specific modifiable risk factors for cardiovascular disease and mortality: evidence from a population-based longitudinal study","volume":"64","author":"Tian","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib20","first-page":"58","article-title":"5-Fluorouracil-related cardiotoxicity; findings from five randomized studies of 5-fluorouracil-based regimens in metastatic colorectal cancer","volume":"18","author":"Abdel-Rahman","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.019_bib21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-023-04538-3","article-title":"Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy","volume":"91","author":"Korver","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.mayocp.2025.08.019_bib22","article-title":"Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: a retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib23","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1093\/oncolo\/oyab035","article-title":"Cardiotoxicity from capecitabine chemotherapy: prospective study of incidence at rest and during physical exercise","volume":"27","author":"Lestuzzi","year":"2022","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3892\/or.2022.8468","article-title":"Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)","volume":"49","author":"Lombardi","year":"2023","journal-title":"Oncol Rep"},{"issue":"16","key":"10.1016\/j.mayocp.2025.08.019_bib25","article-title":"Cardiovascular toxicity of fluoropyrimidines: experience from a quaternary referral center","volume":"42","author":"Chedid El Helou","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2025.08.019_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012798","article-title":"Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer","volume":"6","author":"Polk","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.32471\/exp-oncology.2312-8852.vol-44-no-1.17496","article-title":"Evaluation of 5-fluorouracil-induced cardiotoxicity: role of cardiac biomarkers","volume":"44","author":"Moghaddam","year":"2022","journal-title":"Exp Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2025.08.019_bib28","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.mayocp.2025.08.019_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103346","article-title":"Risk factors of fluoropyrimidine induced cardiotoxicity among cancer patients: a systematic review and meta-analysis","volume":"162","author":"Li","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1875-9114.1997.tb03748.x","article-title":"Symptomatic cardiotoxicity associated with 5-fluorouracil","volume":"17","author":"Meyer","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.mayocp.2025.08.019_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2017.02.009","article-title":"Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group","volume":"76","author":"Kwakman","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.mayocp.2025.08.019_bib32","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1002\/ehf2.14879","article-title":"Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator","volume":"11","author":"Abiodun","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10.1016\/j.mayocp.2025.08.019_bib33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000331645","article-title":"Clinical and electrocardiography changes in patients treated with capecitabine","volume":"57","author":"Koca","year":"2011","journal-title":"Chemotherapy"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaccao.2020.12.005","article-title":"The incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm","volume":"3","author":"Zafar","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"3-4","key":"10.1016\/j.mayocp.2025.08.019_bib35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","article-title":"Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity","volume":"79","author":"Milano","year":"1999","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib36","first-page":"64","article-title":"Efficacy and cardiotoxic safety profile of raltitrexed in fluoropyrimidines-pretreated or high-risk cardiac patients with GI malignancies: large single-center experience","volume":"18","author":"Khan","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib37","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/annonc\/mdf108","article-title":"Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil","volume":"13","author":"Van Cutsem","year":"2002","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2025.08.019_bib38","doi-asserted-by":"crossref","first-page":"e1956","DOI":"10.1634\/theoncologist.2020-0225","article-title":"Adjuvant treatment with 5-fluorouracil and oxaliplatin does not influence cardiac function, neurovascular control, and physical capacity in patients with colon cancer","volume":"25","author":"Groehs","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.mayocp.2025.08.019_bib39","first-page":"430","article-title":"A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center","volume":"62","author":"Khan","year":"2012","journal-title":"J Pak Med Assoc"},{"issue":"7","key":"10.1016\/j.mayocp.2025.08.019_bib40","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E","article-title":"Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer","volume":"72","author":"Sch\u00f6ber","year":"1993","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C","article-title":"The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy","volume":"71","author":"Robben","year":"1993","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib42","first-page":"52","article-title":"Bolus 5-fluorouracil (5-FU) in combination with oxaliplatin is safe and well tolerated in patients who experienced coronary vasospasm with infusional 5-FU or capecitabine","volume":"18","author":"Chakrabarti","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"10.1016\/j.mayocp.2025.08.019_bib43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jjco\/hyi071","article-title":"Cardiotoxicity of de Gramont\u2019s regimen: incidence, clinical characteristics and long-term follow-up","volume":"35","author":"Meydan","year":"2005","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib44","first-page":"e173","article-title":"Real-world evidence on second-line treatment of metastatic colorectal cancer using fluoropyrimidine, irinotecan, and angiogenesis inhibitor","volume":"20","author":"Yamazaki","year":"2021","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.019_bib45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management","volume":"18","author":"Layoun","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"13","key":"10.1016\/j.mayocp.2025.08.019_bib46","first-page":"3028","article-title":"In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C\u2013mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.mayocp.2025.08.019_bib47","article-title":"Impaired microvascular reactivity in patients treated with 5-fluorouracil chemotherapy regimens: potential role of endothelial dysfunction","volume":"49","author":"Hammond","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib48","first-page":"81","article-title":"Endothelin-1 and 5-fluorouracil-induced cardiotoxicity","volume":"45","author":"Porta","year":"1998","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/oxfordjournals.annonc.a058084","article-title":"Very high endothelin plasma levels in patients with 5-FU cardiotoxicity","volume":"3","author":"Thyss","year":"1992","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2025.08.019_bib50","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1159\/000490120","article-title":"Role of urotensin-2 in 5-fluorouracil\u2013related arterial vasoconstriction in cancer patients","volume":"41","author":"Seker","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib51","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12032-009-9226-8","article-title":"5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels","volume":"27","author":"Salepci","year":"2010","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.toxlet.2014.03.018","article-title":"A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives","volume":"227","author":"Lamberti","year":"2014","journal-title":"Toxicol Lett"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1756-9966-31-60","article-title":"5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress","volume":"31","author":"Lamberti","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/00498254.2014.942809","article-title":"A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine","volume":"45","author":"Eskandari","year":"2015","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/0008-5472.CAN-17-1280","article-title":"Atypical G protein \u03b25 promotes cardiac oxidative stress, apoptosis, and fibrotic remodeling in response to multiple cancer chemotherapeutics","volume":"78","author":"Chakraborti","year":"2018","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.mayocp.2025.08.019_bib56","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/009841000156709","article-title":"Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil","volume":"59","author":"Durak","year":"2000","journal-title":"J Toxicol Environ Health A"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115686","article-title":"Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes","volume":"10","author":"Focaccetti","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.019_bib58","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3892\/etm.2021.10886","article-title":"Dynamic observation of 5-fluorouracil\u2013induced myocardial injury and mitochondrial autophagy in aging rats","volume":"22","author":"Li","year":"2021","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.mayocp.2025.08.019_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2273000","article-title":"Protective effect of kaempferol and its nanoparticles on 5-fluorouracil-induced cardiotoxicity in rats","volume":"2022","author":"Safarpour","year":"2022","journal-title":"Biomed Res Int"},{"issue":"7","key":"10.1016\/j.mayocp.2025.08.019_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200060","article-title":"Cardioprotective effect of silymarin nanoemulsion on 5-fluorouracil\u2013induced cardiotoxicity in rats","volume":"355","author":"Safarpour","year":"2022","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.mayocp.2025.08.019_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121523","article-title":"Baicalein prevents capecitabine-induced heart damage in female Wistar rats and enhances its anticancer potential in MCF-7 breast cancer cells","volume":"319","author":"Ibrahim","year":"2023","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.mayocp.2025.08.019_bib62","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00280-023-04529-4","article-title":"Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity","volume":"91","author":"Tambe","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.mayocp.2025.08.019_bib63","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/oxfordjournals.annonc.a010723","article-title":"The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture","volume":"7","author":"Cwikiel","year":"1996","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib64","first-page":"805","article-title":"The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits","volume":"10","author":"Cwikiel","year":"1996","journal-title":"Scanning Microsc"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-Fluorouracil\u2013based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"10.1016\/j.mayocp.2025.08.019_bib66","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1111\/bph.13725","article-title":"5-Fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1","volume":"174","author":"Altieri","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.019_bib67","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1021\/ci0501746","article-title":"Effects of 5-fluorouracil on erythrocytes in relation to its cardiotoxicity: membrane structure and functioning","volume":"45","author":"Spasojevi\u0107","year":"2005","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.mayocp.2025.08.019_bib68","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1196\/annals.1342.028","article-title":"31P NMR spectroscopy and polarographic combined study of erythrocytes treated with 5-fluorouracil: cardiotoxicity-related changes in ATP, 2,3-BPG, and O2 metabolism","volume":"1048","author":"Spasojevi\u0107","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib69","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/molecules14010053","article-title":"Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia","volume":"14","author":"Spasojevi\u0107","year":"2008","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib70","first-page":"571","article-title":"The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart","volume":"12","author":"Millart","year":"1992","journal-title":"Anticancer Res"},{"key":"10.1016\/j.mayocp.2025.08.019_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2022.153113","article-title":"ROS and iron homeostasis dependent ferroptosis play a vital role in 5-fluorouracil induced cardiotoxicity in vitro and in vivo","volume":"468","author":"Li","year":"2022","journal-title":"Toxicology"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib72","first-page":"779","article-title":"Increased iron content in rat myocardium after 5-fluorouracil chronic administration","volume":"13","author":"Millart","year":"1993","journal-title":"Anticancer Res"},{"key":"10.1016\/j.mayocp.2025.08.019_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109241","article-title":"Resveratrol alleviated 5-FU\u2013induced cardiotoxicity by attenuating GPX4 dependent ferroptosis","volume":"112","author":"Li","year":"2023","journal-title":"J Nutr Biochem"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.019_bib74","doi-asserted-by":"crossref","first-page":"970","DOI":"10.21037\/jgo.2017.09.07","article-title":"Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm","volume":"8","author":"Clasen","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100427","article-title":"Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil\u2013based therapy in patients with solid tumours: a multicentre retrospective observational cohort study","volume":"7","author":"Osterlund","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib76","doi-asserted-by":"crossref","first-page":"257.e1-3","DOI":"10.1016\/j.ajem.2010.10.025","article-title":"Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis","volume":"30","author":"\u00c7al\u0131k","year":"2012","journal-title":"Am J Emerg Med"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib77","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/1078155218774871","article-title":"Capecitabine-induced myopericarditis\u2014a case report and review of literature","volume":"25","author":"Saunders","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.mayocp.2025.08.019_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.02.2011.3883","article-title":"5-Fluorouracil induced pericarditis","volume":"2011","author":"Killu","year":"2011","journal-title":"BMJ Case Rep"},{"issue":"12","key":"10.1016\/j.mayocp.2025.08.019_bib79","doi-asserted-by":"crossref","first-page":"775","DOI":"10.5414\/CP204006","article-title":"An unusual case of acute myopericarditis after the first dose of capecitabine: need for new cardioprotective strategies and risk stratification","volume":"59","author":"Meter","year":"2021","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.mayocp.2025.08.019_bib80","article-title":"The first case of severe takotsubo cardiomyopathy associated with 5-fluorouracil in a patient with abnormalities of both dihydropyrimidine dehydrogenase (DPYD) and thymidylate synthase (TYMS) genes","volume":"8","author":"Saif","year":"2016","journal-title":"Cureus"},{"issue":"18","key":"10.1016\/j.mayocp.2025.08.019_bib81","article-title":"Takotsubo syndrome during treatment with 5-fluorouracil","volume":"143","author":"Steen","year":"2023","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"8","key":"10.1016\/j.mayocp.2025.08.019_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.100854","article-title":"Cardio-oncology: capecitabine can sometimes be heatbreaking capecitabine-induced takotsubo cardiomyopathy case report and literature review","volume":"46","author":"Abdelmaseih","year":"2021","journal-title":"Curr Probl Cardiol"},{"issue":"19","key":"10.1016\/j.mayocp.2025.08.019_bib83","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.3390\/jcm10194426","article-title":"Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management","volume":"10","author":"Jurczyk","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib84","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The role of biomarkers in cardio-oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"issue":"5","key":"10.1016\/j.mayocp.2025.08.019_bib85","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jjco\/hyh047","article-title":"Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil\/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers","volume":"34","author":"Oztop","year":"2004","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib86","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2710.2004.00556.x","article-title":"Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion","volume":"29","author":"Ceyhan","year":"2004","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib87","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0003319716637516","article-title":"Usefulness of heart-type fatty acid\u2013binding protein and myocardial performance index for early detection of 5-fluorouracil cardiotoxicity","volume":"68","author":"Turan","year":"2017","journal-title":"Angiology"},{"issue":"4A","key":"10.1016\/j.mayocp.2025.08.019_bib88","first-page":"1883","article-title":"Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients\u2014a pilot study","volume":"27","author":"Holubec","year":"2007","journal-title":"Anticancer Res"},{"issue":"36","key":"10.1016\/j.mayocp.2025.08.019_bib89","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.019_bib90","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10147-005-0516-7","article-title":"5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine","volume":"10","author":"Muneoka","year":"2005","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib91","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1002\/onco.13536","article-title":"Myocardial ischemia induced by 5-fluorouracil: a prospective electrocardiographic and cardiac biomarker study","volume":"26","author":"Dyhl-Polk","year":"2021","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.mayocp.2025.08.019_bib92","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/0277-5379(88)90062-4","article-title":"Circulating drug levels in patients presenting cardiotoxicity to 5-FU","volume":"24","author":"Thyss","year":"1988","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"41","key":"10.1016\/j.mayocp.2025.08.019_bib93","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mayocp.2025.08.019_bib94","author":"Cardinale"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib95","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5603\/KP.a2016.0163","article-title":"Tissue Doppler echocardiography detects subclinical left ventricular dysfunction in patients undergoing chemotherapy for colon cancer: insights from ONCOECHO multicentre study","volume":"75","author":"P\u0142o\u0144ska-Go\u015bciniak","year":"2017","journal-title":"Kardiol Pol"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib96","first-page":"887","article-title":"Left ventricular function in colon cancer patients receiving adjuvant fluoro-folate chemotherapy: an echocardiographic study","volume":"7","author":"Balloni","year":"2000","journal-title":"Oncol Rep"},{"issue":"7","key":"10.1016\/j.mayocp.2025.08.019_bib97","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1023\/A:1008263321681","article-title":"Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study","volume":"8","author":"Grandi","year":"1997","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib98","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0742-2822.2005.03169.x","article-title":"Ultrasound tissue characterization by integrated backscatter for analyzing fluorouracil induced myocardial damage","volume":"22","author":"Ceyhan","year":"2005","journal-title":"Echocardiography"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib99","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000077884","article-title":"A new perspective on cardiotoxicity of 5-fluorouracil. A novel research tool \u201ccardiac ultrasonic integrated backscatter analysis\u201d indicates transient, subclinical myocardial dysfunction due to high-dose leucovorin and infusional 5-fluorouracil regimen","volume":"50","author":"Barutca","year":"2004","journal-title":"Chemotherapy"},{"issue":"11","key":"10.1016\/j.mayocp.2025.08.019_bib100","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib101","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.30321","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","volume":"123","author":"Ma","year":"2017","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.mayocp.2025.08.019_bib102","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1158\/1078-0432.CCR-16-0638","article-title":"FDA approval: uridine triacetate for the treatment of patients following fluorouracil or capecitabine overdose or exhibiting early-onset severe toxicities following administration of these drugs","volume":"22","author":"Ison","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib103","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib104","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines","volume":"21","author":"Shiga","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.019_bib105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"15","key":"10.1016\/j.mayocp.2025.08.019_bib106","article-title":"A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity","volume":"39","author":"Kasi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2025.08.019_bib107","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3109\/02841869009091790","article-title":"Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil","volume":"29","author":"Eskilsson","year":"1990","journal-title":"Acta Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2025.08.019_bib108","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.amjcard.2012.07.026","article-title":"Capecitabine-induced chest pain relieved by diltiazem","volume":"110","author":"Ambrosy","year":"2012","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.mayocp.2025.08.019_bib109","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil\u2013associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.mayocp.2025.08.019_bib110","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/oxfordjournals.annonc.a010800","article-title":"Final results of a randomised trial comparing \u2018Tomudex\u2019 (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. \u201cTomudex\u201d Colorectal Cancer Study Group","volume":"7","author":"Cunningham","year":"1996","journal-title":"Ann Oncol"},{"issue":"9317","key":"10.1016\/j.mayocp.2025.08.019_bib111","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(02)08514-8","article-title":"Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial","volume":"359","author":"Maughan","year":"2002","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.mayocp.2025.08.019_bib112","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.ejca.2008.07.002","article-title":"Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)","volume":"44","author":"Popov","year":"2008","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib113","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdt479","article-title":"Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines","volume":"25","author":"Ransom","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.019_bib114","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/bjc.1998.160","article-title":"Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity","volume":"77","author":"K\u00f6hne","year":"1998","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.mayocp.2025.08.019_bib115","first-page":"2381","article-title":"A phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors","volume":"5","author":"Grem","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.mayocp.2025.08.019_bib116","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2340\/1651-226X.2024.24023","article-title":"Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)","volume":"63","author":"Kinos","year":"2024","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.019_bib117","first-page":"229","article-title":"Long-term safety data on S-1 administered after previous intolerance to capecitabine-containing systemic treatment for metastatic colorectal cancer","volume":"21","author":"Punt","year":"2022","journal-title":"Clin Colorectal Cancer"},{"issue":"12","key":"10.1016\/j.mayocp.2025.08.019_bib118","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/1078-0432.CCR-16-2157","article-title":"FDA Approval Summary: TAS-102","volume":"23","author":"Marcus","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.mayocp.2025.08.019_bib119","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12885-016-2409-8","article-title":"TAS-102, the first \u201ccardio-gentle\u201d fluoropyrimidine in the colorectal cancer landscape?","volume":"16","author":"Petrelli","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib120","first-page":"23","article-title":"Safety and efficacy of s-MOX regimen in patients with colorectal cancer who developed cardiotoxicity following fluoropyrimidine administration: a case series","volume":"2","author":"Ehrlich","year":"2020","journal-title":"Arch Med Case Rep"},{"issue":"12","key":"10.1016\/j.mayocp.2025.08.019_bib121","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.5306\/wjco.v11.i12.1008","article-title":"Fluoropyrimidine-induced cardiotoxicity","volume":"11","author":"Deac","year":"2020","journal-title":"World J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib122","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/02841860310004409","article-title":"Effects of probucol on endothelial damage by 5-fluorouracil","volume":"42","author":"Kinhult","year":"2003","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.019_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/sca.4950230101","article-title":"Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation","volume":"23","author":"Kinhult","year":"2001","journal-title":"Scanning"},{"issue":"7","key":"10.1016\/j.mayocp.2025.08.019_bib124","doi-asserted-by":"crossref","first-page":"17657","DOI":"10.1007\/s11356-022-23314-z","article-title":"Protective effect of quercetin against 5-fluorouracil\u2013induced cardiac impairments through activating Nrf2 and inhibiting NF-\u03baB and caspase-3 activities","volume":"30","author":"Lokman","year":"2023","journal-title":"Environ Sci Pollut Res Int"},{"issue":"4","key":"10.1016\/j.mayocp.2025.08.019_bib125","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jaccao.2025.01.019","article-title":"Fluoropyrimidine chemotherapy and the risk of death and cardiovascular events in patients with gastrointestinal cancer","volume":"7","author":"Abiodun","year":"2025","journal-title":"JACC CardioOncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625004768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625004768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:30:53Z","timestamp":1776288653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619625004768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0025619625004768"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.08.019","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Toxicity of Fluoropyrimidines: What We Know","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}